The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 20, 2024

Filed:

Oct. 07, 2016
Applicants:

David C. Fritzinger, Monroe, NJ (US);

Daniel E. Benjamin, Millstone Township, NJ (US);

Inventors:

David C. Fritzinger, Monroe, NJ (US);

Daniel E. Benjamin, Millstone Township, NJ (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); C07K 14/47 (2006.01); A61P 37/04 (2006.01); A61K 47/10 (2017.01); C12N 15/62 (2006.01); C12N 15/79 (2006.01); C12N 9/64 (2006.01); A61K 38/00 (2006.01); C07K 14/015 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1725 (2013.01); A61K 47/10 (2013.01); A61P 37/04 (2018.01); C07K 14/015 (2013.01); C07K 14/47 (2013.01); C07K 14/472 (2013.01); C12N 15/62 (2013.01); C12N 15/79 (2013.01); A61K 38/00 (2013.01); C12N 9/64 (2013.01); Y02A 50/30 (2018.01);
Abstract

The invention relates generally to a modified human C3 protein containing a number of single amino acid changes in the α and β-chain of human C3 protein, designed to increase the affinity of the modified protein to factor B or Bb, to decrease the affinity of the modified protein to factor H, and to reduce the immunogenicity of the modified protein as compared to the native human C3 protein, a nucleotide sequence encoding the modified C3 protein, a plasmid or viral vector containing the nucleotide sequence for expression the modified C3 protein, and a host cell containing the plasmid or viral vector. We also present a polyethylene glycol covalently bound to the modified C3 protein for reducing immunogenicity and increasing plasma half-life of the modified C3 protein; a method for depleting complement in a patient by administering the modified C3 protein to the patient in an amount effective to deplete complement; a method of ameliorating effects caused by or disease or a method of ameliorating reperfusion injury in a patient by delivering the modified C3 protein.


Find Patent Forward Citations

Loading…